Journal
NATURE CHEMICAL BIOLOGY
Volume 11, Issue 6, Pages 368-372Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nchembio.1813
Keywords
-
Categories
Ask authors/readers for more resources
The pharmaceutical industry continues to experience significant attrition of drug candidates during phase 2 proof-of-concept clinical studies. We describe some questions about the characteristics of protein targets and small-molecule drugs that may be important to consider in drug-discovery projects and could improve prospects for future clinical success.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available